Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): FDA Approves Powerful New Cholesterol Drug

Page 1 of 2

Merck & Co., Inc. (NYSE:MRK) gained Food and Drug Administration approval for its powerful new cholesterol drug Liptruzet, a combination of two already-approved drugs, Pfizer Inc. (NYSE:PFE)‘s Lipitor and Merck’s Zetia.

Merck & Co., Inc. (NYSE:MRK) already sells a combination drug containing Zetia and Zocor called Vytorin. Zocor and Lipitor are in the same class of drugs called statins, but Lipitor is considered more powerful.

In a clinical trial, Liptruzet taken for 12 weeks lowered LDL cholesterol — that’s the bad kind — by 53% to 61% depending on the dose. Lipitor alone in the same trial reduced cholesterol by 37% to 54% depending on the dose. Zetia by itself reduced LDL cholesterol by just 20%.

Interestingly, despite Lipitor being a better statin than Zocor, the LDL cholesterol data doesn’t look that much better than for Vytorin.

In the clinical trial supporting the approval of Vytorin, the combination pill reduced LDL cholesterol by 45% to 60%. It’s difficult to compare results between trials since there may be a different makeup of the subjects enrolled in the trials, but there’s somewhat of an internal control because both trials tested Zetia alone. In the Vytorin trial, the group that got Zetia by itself had a 19% reduction in LDL cholesterol, similar to the 20% seen in the Liptruzet trial.

One advantage of Liptruzet over Vytorin seems to be at the lowest dose — 53% vs. 45% — which could be helpful for patients that can’t tolerate high doses of statins due to side effects including muscle aches.

Assuming they’re priced the same, Merck & Co., Inc. (NYSE:MRK) doesn’t really care whether patients take Liptruzet or Vytorin. The new combination product could help it capture some patients that are currently taking generic Lipitor. It’s easier for a doctor to add a second drug than to change from one drug to two different drugs. Patients could have just added Zetia to their Lipitor, but then they’d have to take two separate pills. Liptruzet is more convenient if nothing else.

Page 1 of 2
Loading Comments...